WHWK Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
22.9M
+26.7%
18.1M
-23.0%
23.5M
-5.5%
24.9M
+27.3%
19.5M
R&D
18.1M
+40.7%
12.9M
-25.2%
17.2M
-9.4%
19.0M
+32.6%
14.3M
SG&A
4.8M
-7.9%
5.2M
-17.1%
6.3M
+7.2%
5.9M
+12.8%
5.2M
Operating Income
-22943000
-26.7%
-18109000
+23.0%
-23522000
+5.5%
-24887000
-27.3%
-19546000
EBITDA
-22943000
-26.7%
-18108000
+23.0%
-23521000
+5.5%
-24886000
-27.4%
-19541000
Net Income
-21209000
-27.5%
-16640000
+25.0%
-22194000
+4.5%
-23251000
-31.0%
-17746000
EPS (Basic)
$-0.23
-15.0%
$-0.20
+37.5%
$-0.32
+5.9%
$-0.34
-30.8%
$-0.26
EPS (Diluted)
$-0.23
-15.0%
$-0.20
+37.5%
$-0.32
+5.9%
$-0.34
-30.8%
$-0.26
Shares (Diluted)
93.9M
+13.2%
82.9M
+19.7%
69.2M
-0.1%
69.3M
+0.2%
69.2M
Whitehawk Therapeutics (WHWK) — Financials